Why Programmable Sterilization Matters for Next-Generation Biologics

The medical sterilization frameworks that have governed device manufacturing for the past four decades were built around a predictable product profile: heat-stable, moisture-tolerant instruments and polymer devices that could withstand the conditions of steam, ethylene oxide, or gamma irradiation without significant property changes. The parameters were broad because the products were tolerant.

The biologics now entering commercial development are not tolerant. Their sterilization requirements are specific, narrow, and interdependent in ways that fixed-parameter sterilization systems — systems designed to run the same validated cycle on everything in the chamber — cannot accommodate. The convergence of cell therapies, gene therapy delivery components, tissue-derived biologics, and combination products with pharmaceutical constituents has created a class of materials where sterilization precision is not a quality attribute to optimize. It is a prerequisite for product viability.

Why Fixed-Parameter Sterilization Fails for Complex Biologics

The inadequacy of fixed-parameter sterilization for next-generation biologics is not a theoretical concern. It follows from the known sensitivities of the biological materials at issue.

**Temperature sensitivity in cell-seeded scaffolds.** Bioabsorbable scaffolds seeded with growth factors, extracellular matrix proteins, or cellular components operate within a narrow thermal window. Published research on VHP sterilization of biological and polymer scaffolds has established that even within the 25–50°C range where VHP operates, temperature selection is consequential. A 2026 study in Pharmaceutical Research examining VHP sterilization of PLGA, PLC, and TPU scaffolds — materials used in tissue engineering and drug delivery applications — confirmed preservation of molecular weight and chemical integrity, with FTIR analysis showing no sterilization-attributable chemical changes. The study's findings were conditioned on controlled process parameters, not a generic VHP exposure. The temperature stability and concentration control of the sterilization system determined whether the polymer chemistry was preserved.

**Concentration thresholds and protein denaturation.** Growth factor coatings, drug-device combinations, and protein-based bioactive layers have hydrogen peroxide concentration tolerance thresholds — exposure above which measurable denaturation or activity loss occurs. These thresholds are product-specific and must be established during process development. A fixed-parameter system running a standard VHP cycle at 500 ppm concentration does not accommodate a growth factor coating that is sensitive above 350 ppm. The only accommodation a fixed-parameter system can offer is rejection: the product is incompatible with the process. A programmable system can develop and validate a cycle at 300 ppm with extended exposure time that achieves SAL 10⁻⁶ within the product's tolerance window.

**Multi-material compatibility.** Many advanced devices combine metallic structural components with biological surface treatments — titanium implants with bone-derived protein coatings, polymer scaffolds with cellular seedings, drug-eluting stents with polymer-drug matrices. Each material has different VHP sensitivity parameters. The sterilization cycle must satisfy all of them simultaneously. In a fixed-parameter system, the validated cycle is optimized for one material profile; the other materials either accept the cycle conditions or they do not. A programmable system with independent control of concentration, temperature, humidity, and time can find the parameter space where all materials in the device are within their validated tolerance windows.

**Moisture sensitivity of specific electronics-integrated systems.** Implantable sensors, wearable therapeutic devices, and hybrid devices containing moisture-sensitive electronic components cannot tolerate the high-humidity conditions of some EtO cycles. VHP's programmable humidity control allows cycles to be developed at lower absolute humidity — within the moisture tolerance of sensitive electronics — while maintaining the VHP concentration distribution necessary for efficacy.

What Programmable Parametric Control Actually Means

In PuroGen's SteriFlex platform, programmable parametric control refers to independent, step-wise specification of five critical parameters across multiple cycle phases:

**VHP Concentration** is adjustable across a validated range in precise increments. The relationship between concentration and microbial inactivation rate (the D-value relationship) means that lower concentrations require proportionally longer exposure times to achieve the same log reduction. Programmable concentration control allows the system to balance inactivation kinetics against oxidative stress on sensitive materials — running lower concentrations with extended time for sensitive products, or higher concentrations with shorter exposure for products that are less concentration-sensitive.

**Temperature** is controllable between 25°C and 50°C with stability tolerances that matter for temperature-sensitive materials. The 25-degree range across which SteriFlex operates is not incidental — it spans the difference between conditions appropriate for the most thermally sensitive biologics and conditions appropriate for less sensitive polymer devices. A fixed-cycle system that runs at a single temperature point cannot serve both ends of that range.

**Relative Humidity** affects VHP condensation behavior, chamber distribution kinetics, and the interaction between hydrogen peroxide vapor and hydrophilic surfaces. Humidity management is particularly relevant for porous substrates, hydrophilic biological matrices, and hygroscopic packaging materials. Independent humidity control allows the conditioning phase of the cycle to be optimized for the specific product configuration.

**Exposure Time** is specified per cycle phase — conditioning, sterilization, aeration — with validated hold times for each. Multi-phase cycle design allows different parameter profiles within a single run: a higher-concentration conditioning phase followed by a lower-concentration, longer-duration sterilization phase optimized for material compatibility. This phase structure is the operational expression of process development findings.

**Aeration** is controlled to ensure complete VHP decomposition before product release. For most products, VHP residuals fall below detection thresholds within the aeration phase. For materials with specific hydrogen peroxide sensitivity, the aeration profile can be extended and monitored to confirm residual levels below the validated limit established in the ISO 22441 Section 5.4.5 residue risk assessment.

The Validated Parameter Envelope: A Different Approach to Validation

Conventional sterilization validation establishes a single validated operating point — a specific set of parameter values at which the process is demonstrated to achieve SAL 10⁻⁶. Subsequent production runs must reproduce those exact conditions. Variation from the validated point triggers a deviation.

Parameter envelope validation, the approach used in PuroGen's SteriFlex implementations, defines validated ranges rather than single points. During process development, the boundary conditions of acceptable performance are characterized: the minimum VHP concentration at which the biological indicator challenge is reliably inactivated, the maximum temperature at which the biological material is not measurably affected, the humidity range within which VHP distribution achieves adequate uniformity. The validated operating space is a multi-dimensional envelope rather than a point.

Within that envelope, routine production runs have operational flexibility. A batch that runs at 410 ppm rather than the target 400 ppm is within the validated range — not a deviation requiring investigation. A new product with a slightly different biological sensitivity can be validated within the existing envelope with targeted testing rather than a full system revalidation, provided its parameters fall within the established range.

This approach is consistent with ISO 22441:2022 and with FDA's current sterilization validation thinking — which has moved toward lifecycle-based process understanding rather than single-point validation. It requires more comprehensive process development work upfront, but it produces a more robust and flexible validated state for ongoing production.

Applications: Where Programmable Sterilization Is Not Optional

**Demineralized bone matrix and tissue-derived osteoinductive products.** DBM's clinical value is its growth factor content — bone morphogenetic proteins, TGF-β, and related signaling molecules exposed during demineralization. These proteins are temperature-sensitive and oxidatively sensitive. The sterilization cycle for DBM must operate within the specific parameter range where microbial inactivation is achieved and growth factor activity is preserved. For a product whose osteoinductive capacity is its clinical rationale, sterilization parameters are not secondary to the product specification — they are part of it.

**Combination products with drug or biologic coatings.** The FDA's guidance on combination product development explicitly identifies terminal sterilization as a process that can alter drug or biological product constituent quality attributes. For drug-eluting polymer coatings, antibiotic-impregnated materials, and growth factor-functionalized surfaces, the sterilization cycle must be developed and validated within the coating's material compatibility window. Programmable concentration and temperature control allow that window to be identified during process development and honored during validated production.

**Personalized and patient-matched devices.** Additive manufacturing has enabled a device category — personalized implants sized and shaped to specific patient anatomy — where batch sizes may be as small as one unit. The sterilization process for patient-matched devices must be validated for the device category, not re-validated for each individual unit. A programmable system with validated parameter envelopes can accommodate the geometric variability inherent in personalized manufacturing within the validated operating space.

**Next-generation biologics in development pipelines.** Organizations developing lentiviral vector delivery components, cell therapy scaffolds, or regenerative medicine combination products face sterilization decisions early in development that will constrain their regulatory and manufacturing options downstream. Building the process development infrastructure around a programmable sterilization system creates the technical capacity to accommodate the specific biological sensitivities each product reveals during development, rather than forcing the product to conform to a fixed sterilization profile.

Frequently Asked Questions

**What is parameter envelope validation, and how does it differ from single-point validation?**

Single-point validation demonstrates that a sterilization process achieves SAL 10⁻⁶ at one specific combination of parameter values. Parameter envelope validation characterizes the ranges across which the process reliably achieves SAL 10⁻⁶ — establishing minimum and maximum bounds for each parameter within which performance is validated. The envelope approach is supported by ISO 22441:2022 and provides operational flexibility for routine production (variations within the validated range are not deviations) and faster qualification of new products within the established envelope. It requires more comprehensive process development work but produces a more robust and adaptable validated state.

**How does programmable VHP sterilization handle materials with conflicting parameter requirements within the same device?**

The process development phase under ISO 22441 includes material compatibility assessment for all materials in the device's bill of materials. When materials have different sensitivity profiles — a metallic component that tolerates higher VHP concentrations and a biological coating that requires lower concentrations — the process development objective is to identify parameter conditions that satisfy both. Multi-phase cycle design allows different conditions in different phases of the same run (e.g., a low-concentration conditioning phase followed by a longer sterilization phase). Where no single parameter set satisfies all materials, the finding drives a design decision — typically a packaging or formulation change — before the sterilization cycle is finalized.

**What biological indicators are used for programmable VHP validation, and how is the half-cycle method applied?**

ISO 22441:2022 specifies *Geobacillus stearothermophilus* as the reference biological indicator organism for VHP sterilization validation. In parameter envelope validation, biological indicator challenges are conducted at multiple points within the validated envelope to characterize the D-value relationship across the parameter range — establishing that the inactivation kinetics are predictable and consistent throughout the operating space. Performance qualification uses the half-cycle method: three consecutive PQ runs at reduced parameters (half the exposure of the full validated cycle) must achieve no growth in biological indicators inoculated at a minimum population of 10⁶ spores, demonstrating the full cycle's safety margin.

**What makes VHP sterilization compatible with temperature-sensitive biologics where steam and EtO are not?**

Steam sterilization operates at 121–134°C — temperatures that denature proteins, destroy biological activity, and are incompatible with essentially all biologics and sensitive polymer materials. Ethylene oxide operates at lower temperatures (37–63°C) but requires post-sterilization aeration to clear residue, and EtO residue interacts with protein and drug components in ways that can alter activity. VHP operates at 25–50°C without ionizing radiation and without leaving chemical residue — hydrogen peroxide vapor decomposes completely to water and oxygen. At temperatures below 50°C, most biological proteins retain their tertiary structure and activity. This temperature profile, combined with zero residue and the programmable control that allows the specific temperature window appropriate to each biological product to be identified and validated, is what makes VHP the appropriate sterilization method for the biologic product categories described here.

**Can a single SteriFlex system validate and run multiple products with different parameter sets?**

Yes. Each product is validated against its own parameter set — its own validated operating envelope — on the same system. The system's IQ and OQ cover the system's operating range. PQ is executed per product or product family, documenting the specific parameter envelope within which each product's sterilization process is validated. A system running three products with three different validated cycles operates with independent validation documentation for each cycle. Cycle identification in electronic batch records ensures the correct validated cycle is executed for each production run, with full parametric data captured for each.